Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1133166

	registered interest
	date	19/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	266861
	answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:42:09 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4623 label Biography information for Tonia Antoniazzi

1133167

	registered interest
	date	19/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	266862
	answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:43:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4623 label Biography information for Tonia Antoniazzi

1133326

	registered interest
	date	19/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many licences have been issued for the prescription of medicinal cannabis.
	tabling member constituency	Burton
	tabling member printed	Andrew Griffiths
	uin	266815
	answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The law stipulates that any doctor on the General Medical Council’s Specialist Register can prescribe cannabis-based products for medicinal use. No licences are required to prescribe.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:40:10 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3936 label Biography information for Andrew Griffiths

1132764

	registered interest
	date	18/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	What progress the Government has made on making medical cannabis available to people who need it.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	911421
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.</p><p /><p /> answering member constituency West Suffolk answering member printed Matt Hancock question first answered 18/06/2019 16:50:49 answering member 4070 label Biography information for Matt Hancock
	tabling member	4623 label Biography information for Tonia Antoniazzi

1132025

	registered interest
	date	13/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how and by whom medical cannabis was produced in the UK before its legalisation.
	tabling member constituency	Central Ayrshire
	tabling member printed	Dr Philippa Whitford
	uin	264425
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>Prior to the change of the law on 1 November 2018, only cannabis-based products that had been given a marketing authorisation (product licence) by the medicines regulators, the Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency could be prescribed. Before issuing a marketing authorisation the MHRA accesses all the available evidence on efficacy and safety arising out of pre-clinical research and clinical trials and evidence and information supplied by the manufacturer. The regulators also inspect the factory where the medicine is to be made, to make sure that supplies will be of a uniformly and consistently high standard.</p><p> </p><p>The following cannabis-based products and related products received a marketing authorisation in the United Kingdom/European Union before 1 November 2018:</p><p> </p><p>- Sativex - (produced by GW Pharmaceuticals) containing tetrahydrocannabinol (THC) and cannabidiol - holds a licence for spasticity in multiple sclerosis; and</p><p>- Nabilone - (multiple manufacturers) which contains a synthetic, non-natural cannabinoid which mimics THC, holds a marketing authorisation for nausea and vomiting caused by chemotherapy.</p><p> </p><p>In addition, Epidiolex (also produced by GW Pharmaceuticals from cannabis) for two severe forms of intractable epilepsy (Lennox-Gastaut Syndrome or Dravet Syndrome), is currently being considered for a marketing authorisation by the European Medicines Agency.</p><p> </p><p>The change in the law allows the prescription, by specialist doctors on the General Medical Council’s Specialist Register, of cannabis-based products that have not been through this rigorous process but that meet certain quality standards in cases where all licensed products have been considered and discounted and it is in the best interest of the patient. It also makes</p><p>it easier and will incentivise further research into the potential health benefits of cannabis-based products and the development of further licensed products for more routine use in the health service.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:31:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4385 label Biography information for Dr Philippa Whitford

1131293

	registered interest
	date	11/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many companies are licensed to sell cannabis products to the NHS.
	tabling member constituency	Ross, Skye and Lochaber
	tabling member printed	Ian Blackford
	uin	263171
	answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p> </p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and non-objection to import from the MHRA for each individual import of a controlled drug.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 09:39:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4390 label Biography information for Ian Blackford

1131321

	registered interest
	date	11/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress he has made on ensuring that medical cannabis is available to people who need it.
	tabling member constituency	Birkenhead
	tabling member printed	Frank Field
	uin	263063
	answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients.</p><p>Interim clinical guidance has been issued by the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists to support doctors looking to prescribe cannabis-based products. The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of cannabis-based medicinal products, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:21:18 answering member 4455 label Biography information for Seema Kennedy
	tabling member	478 label Biography information for Lord Field of Birkenhead